These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 25359362)

  • 41. Pharmaceutical sciences in 2020.
    Crommelin D; Stolk P; Besançon L; Shah V; Midha K; Leufkens H
    Nat Rev Drug Discov; 2010 Feb; 9(2):99-100. PubMed ID: 20118959
    [No Abstract]   [Full Text] [Related]  

  • 42. Achieving continuous manufacturing for final dosage formation: challenges and how to meet them. May 20-21, 2014 Continuous Manufacturing Symposium.
    Byrn S; Futran M; Thomas H; Jayjock E; Maron N; Meyer RF; Myerson AS; Thien MP; Trout BL
    J Pharm Sci; 2015 Mar; 104(3):792-802. PubMed ID: 25501530
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interview with Solomon Nwaka.
    Nwaka S
    Future Med Chem; 2011 Sep; 3(11):1339-44. PubMed ID: 21879840
    [TBL] [Abstract][Full Text] [Related]  

  • 44. U-BIOPRED: evaluation of the value of a public-private partnership to industry.
    Riley JH; Erpenbeck VJ; Matthews JG; Holweg CTJ; Compton C; Seibold W; Higenbottam T; Wagers S; Rowe A; Myles D;
    Drug Discov Today; 2018 Sep; 23(9):1622-1634. PubMed ID: 29936248
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Informatics for neglected diseases collaborations.
    Bost F; Jacobs RT; Kowalczyk P
    Curr Opin Drug Discov Devel; 2010 May; 13(3):286-96. PubMed ID: 20443162
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Crowdsourcing in pharma: a strategic framework.
    Bentzien J; Bharadwaj R; Thompson DC
    Drug Discov Today; 2015 Jul; 20(7):874-83. PubMed ID: 25637169
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Professional medical associations and the opportunity to promote breakthrough biomedical innovation.
    Xu S; Xu RS; Breslin J; Raff AB; Garibyan L; Sunshine JC; Ju WD
    Drug Discov Today; 2018 Aug; 23(8):1453-1456. PubMed ID: 29391260
    [No Abstract]   [Full Text] [Related]  

  • 48. [Cohorts and registers: Which public/private partnerships to choose?].
    Jouan-Flahault C; Landais P; Thomas R; Parker S; Genevaz D
    Presse Med; 2012 May; 41 Suppl 1():S15-9. PubMed ID: 22464892
    [No Abstract]   [Full Text] [Related]  

  • 49. Drugs for Neglected Diseases initiative model of drug development for neglected diseases: current status and future challenges.
    Ioset JR; Chang S
    Future Med Chem; 2011 Sep; 3(11):1361-71. PubMed ID: 21879842
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Public-private partnerships for health--what does the evidence say?
    Thomason J; Rodney A
    P N G Med J; 2009; 52(3-4):166-78. PubMed ID: 21877579
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Public-Private Partnerships in Lead Discovery: Overview and Case Studies.
    Gottwald M; Becker A; Bahr I; Mueller-Fahrnow A
    Arch Pharm (Weinheim); 2016 Sep; 349(9):692-7. PubMed ID: 27335205
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Racing to define pharmaceutical R&D external innovation models.
    Wang L; Plump A; Ringel M
    Drug Discov Today; 2015 Mar; 20(3):361-70. PubMed ID: 25448753
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Progress in public-private partnerships to fight neglected diseases.
    Gustavsen K; Hanson C
    Health Aff (Millwood); 2009; 28(6):1745-9. PubMed ID: 19887415
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Empowering industrial research with shared biomedical vocabularies.
    Harland L; Larminie C; Sansone SA; Popa S; Marshall MS; Braxenthaler M; Cantor M; Filsell W; Forster MJ; Huang E; Matern A; Musen M; Saric J; Slater T; Wilson J; Lynch N; Wise J; Dix I
    Drug Discov Today; 2011 Nov; 16(21-22):940-7. PubMed ID: 21963522
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Industry is more alarmed about reproducibility than academia.
    Bespalov A; Barnett AG; Begley CG
    Nature; 2018 Nov; 563(7733):626. PubMed ID: 30487623
    [No Abstract]   [Full Text] [Related]  

  • 56. Public Health Accreditation and Collaborative Partnerships.
    Ishcomer J; Hewlett Noël W; Coffman J
    J Public Health Manag Pract; 2018; 24 Suppl 3():S51-S54. PubMed ID: 29595599
    [No Abstract]   [Full Text] [Related]  

  • 57. Reaping the benefits of biomedical research: partnerships required.
    Portilla LM; Alving B
    Sci Transl Med; 2010 Jun; 2(35):35cm17. PubMed ID: 20538616
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Big science for vaccine development.
    Rappuoli R; Medaglini D
    Vaccine; 2014 Aug; 32(37):4705-7. PubMed ID: 24975815
    [No Abstract]   [Full Text] [Related]  

  • 59. How the Kidney Health Initiative Catalyzes Innovation in a Dynamic Environment.
    Harris RC; Cahill Z
    Clin J Am Soc Nephrol; 2020 Mar; 15(3):421-422. PubMed ID: 31810991
    [No Abstract]   [Full Text] [Related]  

  • 60. The PCAST report: impact and implications for the pharmaceutical industry.
    Morris SA; Rosenblatt M; Orloff JJ; Lewis-Hall F; Waldstreicher J
    Clin Pharmacol Ther; 2013 Sep; 94(3):300-2. PubMed ID: 23963216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.